Norton Healthcare physicians first in world to test cancer drug as COVID-19 treatment
A COVID-19 patient at Norton Healthcare is the first in the world to participate in a randomized Phase 2 clinical study using low-dose selinexor. This oral drug, manufactured by Karyopharm Therapeutics Inc. and marketed as XPOVIO, is currently approved at higher doses […]
View more
Pancreatic adenocarcinoma study published in Annals of Surgical Oncology
Robert C. G. Martin II, M.D., Ph.D., has published research in Annals of Surgical Oncology, in a paper titled “Evaluating the Regulatory Immunomodulation Effect of Irreversible Electroporation (IRE) in Pancreatic Adenocarcinoma.” Dr. Martin is a […]
View more
Research is spine group’s hallmark
It’s not unusual for the presence and expertise of Norton Leatherman Spine surgeons to be requested at medical conferences around the world. This year alone, Norton Leatherman Spine physicians served as keynote speakers at spine […]
View more
Norton Cancer Institute researching how to reduce infections linked to treating AML
Nohla Therapeutics initiates Phase 2 LAUNCH clinical trial to assess optimal dosage of innovative cell therapy for those with acute myeloid leukemia. A treatment made from umbilical cord blood is helping oncology and hematology specialists […]
View more
Research program offers clinicians opportunities
Norton Healthcare offers a wide range of research opportunities for clinicians and their practice groups, as well as clinicians partnering from other entities. More than 850 studies were active or pending through mid-December 2017. “Norton […]
View more
Norton Children’s Cancer Institute launches
Norton Cancer Institute and Norton Children’s Hospital, in affiliation with the University of Louisville, have founded Norton Children’s Cancer Institute to provide improved access, new programs to treat rare tumors and benign blood disorders, and […]
View more
First patient consents to lymphoma trial
Norton Cancer Institute has enlisted the first patient ever to participate in a clinical trial studying a potential new drug to treat a type of rare lymphoma. The female patient will receive a drug designed […]
View more
Refractory epilepsy treatments available
Patients with refractory epilepsy face a greater risk of accidents, injuries, cognitive issues, mood disorders, social difficulties and unemployment. Norton Neuroscience Institute offers a variety of treatments that can vastly improve quality of life for these patients, […]
View more